Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23557
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheung, Ada S-
dc.contributor.authorHoermann, Rudolf-
dc.contributor.authorGhasem-Zadeh, Ali-
dc.contributor.authorTinson, Alistair J-
dc.contributor.authorLy, Vivian-
dc.contributor.authorMilevski, Stefan V-
dc.contributor.authorLim Joon, Daryl-
dc.contributor.authorZajac, Jeffrey D-
dc.contributor.authorSeeman, Ego-
dc.contributor.authorGrossmann, Mathis-
dc.date2020-06-16-
dc.date.accessioned2020-06-18T00:24:58Z-
dc.date.available2020-06-18T00:24:58Z-
dc.date.issued2020-10-
dc.identifier.citationJournal of Bone and Mineral Research 2020; 35(10): 1871-1880en
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23557-
dc.description.abstractAndrogen deprivation therapy (ADT) given to men with prostate cancer causes rapid and severe sex steroid deficiency leading to increased bone remodeling and accelerated bone loss. To examine the effects of a single dose of zoledronic acid on bone microarchitecture we conducted a two year randomised placebo controlled trial in 76 men, mean age [IQR] 67.8 years [63.8;73.9] with non-metastatic prostate cancer commencing adjuvant ADT; 39 were randomised to zoledronic acid and 37 to matching placebo. Bone microarchitecture was measured using high resolution-peripheral quantitative computed tomography (HR-pQCT). Using a mixed model, mean adjusted differences (MAD [95% CI]) between the groups are reported as the treatment effect at several time points. Over 24 months, zoledronic acid showed no appreciable treatment effect on the primary outcomes for total volumetric bone mineral density (vBMD); radius (6.7 mg HA/cm3 [-2.0;15.4], p=0.21) and tibia (1.9 mg HA/cm3 [-3.3;7.0], p=0.87). Similarly, there were no between group differences in other measures of microarchitecture, with the exception of a modest effect of zoledronic acid over placebo in total cortical vBMD at the radius over 12 months (17.3 mgHA/cm3 [5.1;29.5]). In contrast, zoledronic acid showed a treatment effect over 24 months on aBMD by DXA at all sites, including lumbar spine (0.10 g/cm2 [0.07;0.13]), p<0.001), and total hip (0.04 g/cm2 [0.03;0.05], p<0.001). Bone remodeling markers were initially suppressed in the treatment group then increased but remained lower relative to placebo (MADs at 24 months CTX -176 ng/l [-275;-76], p<0.001, P1NP -18 mg/L [-32;-5], p<0.001). These findings suggest that a single dose of zoledronic acid over 2 years is ineffective in preventing the unbalanced bone remodeling and severe microstructural deterioration associated with ADT therapy. This article is protected by copyright. All rights reserved.en
dc.language.isoeng-
dc.subjectAndrogen deprivationen
dc.subjectbisphosphonatesen
dc.subjectboneen
dc.subjectmicroarchitectureen
dc.subjectProstate canceren
dc.titleDiffering effects of zoledronic acid on bone microarchitecture and bone mineral density in men receiving androgen deprivation therapy: a randomised controlled trial.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Bone and Mineral Researchen
dc.identifier.affiliationDepartment of Endocrinology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1002/jbmr.4106en
dc.type.contentTexten
dc.identifier.orcid0000-0002-9692-048Xen
dc.identifier.orcid0000-0001-8261-3457en
dc.identifier.orcid0000-0001-5257-5525en
dc.identifier.orcid0000-0002-1326-4270en
dc.identifier.orcid0000-0002-1947-9694en
dc.identifier.orcid0000-0003-3933-5708en
dc.identifier.orcid0000-0001-8261-3457en
dc.identifier.pubmedid32542695-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.